A Systematic Review and Meta-Analysis: Adverse Inflammatory Bowel Disease Outcomes Following Acute COVID-19

Overview

Journal Gastro Hep Adv

Date 2025 Feb 10

PMID 39926204

Authors

Evangelin Shaloom Vitus

Simran Mann

Charlie W Lees

Tine Jess

Rahma Elmahdi

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Respiratory viral infections have been implicated in the exacerbation of immune-mediated inflammatory diseases such as inflammatory bowel disease (IBD). To understand the impact of early SARS-CoV-2 variants on the risk of adverse IBD outcomes, we aimed to perform a meta-analysis of high-quality studies.

Methods: Cohort studies investigating adverse IBD outcomes (IBD flares, change in disease activity, change in medication, IBD-related hospitalization, and surgery) following COVID-19 were retrieved from MEDLINE and Embase. The Risk Of Bias In Nonrandomized Studies-of Exposure tool was used to assess risk of bias. Random effects model meta-analysis was used to calculate the hazard ratio (HR) for risk of adverse outcomes. Subgroup analysis was performed to estimate risk of outcomes for ulcerative colitis and Crohn's disease patients. Metaregression was performed for sex and duration of follow-up.

Results: Of the 3119 identified studies, 5 were included in the meta-analysis. A total of 34,977 IBD patients with COVID-19 and 53,270 IBD patients without recorded COVID-19 infection were identified. Two of the studies showed a high risk of bias. The random effects model did not show a statistically significant increase in the risk of adverse IBD outcomes following COVID infection (HR:1.05 [0.75-1.46]). There was no significant difference in adverse outcomes between Crohn's disease (HR: 0.91 [0.82-1.02]) and ulcerative colitis patients (HR: 0.83 [0.76-0.90]). Neither the proportion of male participants nor the mean duration of follow-up were found to be significant predictors of effect size.

Conclusion: In this systematic review and meta-analysis, we find that COVID-19 did not increase the risk of adverse IBD outcomes.

References

Hong S, Bhattacharya S, Aboubakr A, Nadkarni D, Lech D, Ungaro R . COVID-19 is not associated with worse long-term inflammatory bowel disease outcomes: a multicenter case-control study. Therap Adv Gastroenterol. 2022; 15:17562848221132363. PMC: 9637830. DOI: 10.1177/17562848221132363. View

Xavier R, Podolsky D . Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007; 448(7152):427-34. DOI: 10.1038/nature06005. View

Al-Aly Z, Bowe B, Xie Y . Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022; 28(7):1461-1467. PMC: 9307472. DOI: 10.1038/s41591-022-01840-0. View

Qazi T, Amaratunga T, Barnes E, Fischer M, Kassam Z, Allegretti J . The risk of inflammatory bowel disease flares after fecal microbiota transplantation: Systematic review and meta-analysis. Gut Microbes. 2017; 8(6):574-588. PMC: 5730391. DOI: 10.1080/19490976.2017.1353848. View

Irving P, Gibson P . Infections and IBD. Nat Clin Pract Gastroenterol Hepatol. 2008; 5(1):18-27. DOI: 10.1038/ncpgasthep1004. View

Herrera-De Guise C, Mayorga Ayala L, Serra Ruiz X, Alonso V, Sainz N, Ibarz A . Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak. Rev Esp Enferm Dig. 2022; 115(6):315-319. DOI: 10.17235/reed.2022.8668/2022. View

Gradel K, Nielsen H, Schonheyder H, Ejlertsen T, Kristensen B, Nielsen H . Increased short- and long-term risk of inflammatory bowel disease after salmonella or campylobacter gastroenteritis. Gastroenterology. 2009; 137(2):495-501. DOI: 10.1053/j.gastro.2009.04.001. View

Tripathi K, Godoy Brewer G, Nguyen M, Singh Y, Ismail M, Sauk J . COVID-19 and Outcomes in Patients With Inflammatory Bowel Disease: Systematic Review and Meta-Analysis. Inflamm Bowel Dis. 2021; 28(8):1265-1279. PMC: 8574492. DOI: 10.1093/ibd/izab236. View

Tarris G, de Rougemont A, Charkaoui M, Michiels C, Martin L, Belliot G . Enteric Viruses and Inflammatory Bowel Disease. Viruses. 2021; 13(1). PMC: 7828589. DOI: 10.3390/v13010104. View

10.

Mylonaki M, Langmead L, Pantes A, Johnson F, Rampton D . Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol. 2004; 16(8):775-8. DOI: 10.1097/01.meg.0000131040.38607.09. View

11.

Salvatori S, Baldassarre F, Mossa M, Monteleone G . Long COVID in Inflammatory Bowel Diseases. J Clin Med. 2021; 10(23). PMC: 8658587. DOI: 10.3390/jcm10235575. View

12.

Ungaro R, Mehandru S, Allen P, Peyrin-Biroulet L, Colombel J . Ulcerative colitis. Lancet. 2016; 389(10080):1756-1770. PMC: 6487890. DOI: 10.1016/S0140-6736(16)32126-2. View

13.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

14.

Norgard B, Zegers F, Nielsen J, Knudsen T, Kjeldsen J . COVID-19 Does Not Lead to an Increase in Corticosteroid Prescriptions in IBD Patients: A Nationwide Cohort Study. Inflamm Bowel Dis. 2023; 29(9):1470-1476. DOI: 10.1093/ibd/izad070. View

15.

Wright B, Tideman S, Diaz G, French T, Parsons G, Robicsek A . Comparative vaccine effectiveness against severe COVID-19 over time in US hospital administrative data: a case-control study. Lancet Respir Med. 2022; 10(6):557-565. PMC: 8881000. DOI: 10.1016/S2213-2600(22)00042-X. View

16.

Lukin D, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W . No Durable Impact of COVID-19 on Intestinal Disease Activity in Subjects With IBD. Clin Gastroenterol Hepatol. 2021; 19(11):2312-2314.e3. PMC: 8178538. DOI: 10.1016/j.cgh.2021.06.008. View

17.

Guerra I, Algaba A, Jimenez L, Mar Aller M, Garza D, Bonillo D . Incidence, Clinical Characteristics, and Evolution of SARS-CoV-2 Infection in Patients With Inflammatory Bowel Disease: A Single-Center Study in Madrid, Spain. Inflamm Bowel Dis. 2020; 27(1):25-33. PMC: 7499624. DOI: 10.1093/ibd/izaa221. View

18.

Ananthakrishnan A, Bernstein C, Iliopoulos D, MacPherson A, Neurath M, Raja Ali R . Environmental triggers in IBD: a review of progress and evidence. Nat Rev Gastroenterol Hepatol. 2017; 15(1):39-49. DOI: 10.1038/nrgastro.2017.136. View

19.

Zhang H, Zhao S, Cao Z . Impact of Epstein-Barr virus infection in patients with inflammatory bowel disease. Front Immunol. 2022; 13:1001055. PMC: 9651941. DOI: 10.3389/fimmu.2022.1001055. View

20.

Amiot A, Rahier J, Baert F, Nahon S, Hart A, Viazis N . The Impact of COVID-19 on Patients with IBD in a Prospective European Cohort Study. J Crohns Colitis. 2022; 17(1):37-48. PMC: 9384408. DOI: 10.1093/ecco-jcc/jjac091. View